The U.S. Food and Drug Administration (FDA) has issued an Abbreviated New Drug Application (ANDA) number ANDA084080 for a promethazine hydrochloride product submitted by TABLICAPS.
The product is an oral tablet containing 12.5 mg of promethazine hydrochloride, classified under the route "ORAL" and dosage form "TABLET". The sponsor indicated that the product is not a reference drug and is listed with a marketing status of "Discontinued".
No reference standard was provided for this submission.
Regulatory UpdatesSep 19, 2026•1 min read
FDA Issues ANDA084080 for Promethazine Hydrochloride Tablet
FDA assigned ANDA084080 to TABLICAPS for an oral 12.5 mg promethazine hydrochloride tablet, now listed as discontinued.
Compiled by the PharmaCountry team · Source: FDA.gov
Ratings
(0)
(0)
(0)
(0)
(0)
More articles
View all insightsResearch & Reports
Global Finished Dosage Manufacturing Landscape 2026
Oct 5, 2026
Regulatory UpdatesKorea Korus hit with 1‑month manufacturing suspension over missing post‑marketing safety test
Sep 28, 2026
AnalysisPharma distributors set delivery cut‑offs ahead of Chuseok holiday (Sep 21‑23)
Sep 28, 2026
Leave your rating